Literature DB >> 14693112

Adjunctive dexamethasone treatment in acute bacterial meningitis.

Abhijit Chaudhuri1.   

Abstract

The initiation of antibiotic treatment on suspicion of bacterial meningitis is important, but it is not enough to improve the prognosis for patients, especially those with pneumococcal meningitis. The mortality and morbidity of pneumococcal meningitis are still devastating, and results of a recent randomised trial have shown evidence in favour of dexamethasone treatment given before or with the first antibiotic dose. Adjuvant dexamethasone is unequivocally recommended in children and adults with haemophilus meningitis or pneumococcal meningitis. The benefit of adjunctive dexamethasone is likely to be greatest in patients who are otherwise healthy and present early with acute bacterial meningitis. Dexamethasone is not currently recommended for the treatment of gram-negative bacillary meningitis and neonatal meningitis. Dexamethasone, before or with the first dose of antibiotic, is likely to be one of the most significant practice changes that will benefit many adults and children with common types of acute bacterial meningitis and has been of proven value in the developed world.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693112     DOI: 10.1016/s1474-4422(03)00623-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  12 in total

1.  Persisting vasculitis after pneumococcal meningitis.

Authors:  Deborah Pugin; Jean-Christophe Copin; Marie-Christelle Goodyear; Theodor Landis; Yvan Gasche
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

2.  [Not Available].

Authors:  Guillaume Sébire; Claude Cyr
Journal:  Paediatr Child Health       Date:  2006-01       Impact factor: 2.253

3.  Response to 'Benefits of glucocorticoids in the treatment of bacterial meningitis in children: End of the controversy?'.

Authors:  James D Kellner
Journal:  Paediatr Child Health       Date:  2006-01       Impact factor: 2.253

Review 4.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

5.  Multiple therapeutic effects of adjunctive baicalin therapy in experimental bacterial meningitis.

Authors:  Yong-Jun Tang; Fu-Wen Zhou; Zi-Qiang Luo; Xin-Zhong Li; Hui-Ming Yan; Ming-Jie Wang; Fu-Rong Huang; Shao-Jie Yue
Journal:  Inflammation       Date:  2010-06       Impact factor: 4.092

6.  Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial.

Authors:  E Soemirien Kasanmoentalib; Mercedes Valls Seron; B Paul Morgan; Matthijs C Brouwer; Diederik van de Beek
Journal:  J Neuroinflammation       Date:  2015-08-15       Impact factor: 8.322

7.  Spontaneous gram-negative bacillary meningitis in adult patients: characteristics and outcome.

Authors:  Virginia Pomar; Natividad Benito; Joaquin López-Contreras; Pere Coll; Mercedes Gurguí; Pere Domingo
Journal:  BMC Infect Dis       Date:  2013-09-30       Impact factor: 3.090

8.  Characteristics and outcome of spontaneous bacterial meningitis in patients with cancer compared to patients without cancer.

Authors:  Virginia Pomar; Natividad Benito; Joaquin López-Contreras; Pere Coll; Mercedes Gurguí; Pere Domingo
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

9.  Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus.

Authors:  Virginia Pomar; Natividad de Benito; Albert Mauri; Pere Coll; Mercè Gurguí; Pere Domingo
Journal:  BMC Infect Dis       Date:  2020-04-20       Impact factor: 3.090

10.  High-throughput sequencing of 16S rDNA amplicons characterizes bacterial composition in cerebrospinal fluid samples from patients with purulent meningitis.

Authors:  Aicui Liu; Chao Wang; Zhijuan Liang; Zhi-Wei Zhou; Lin Wang; Qiaoli Ma; Guowei Wang; Shu-Feng Zhou; Zhenhai Wang
Journal:  Drug Des Devel Ther       Date:  2015-08-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.